Healthy Skepticism Library item: 11282

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Colmenero F, Sullivan SD, Palmer JA, Brauer CA, Bungay K, Watkins J, Neumann PJ.
Quality of clinical and economic evidence in dossier formulary submissions.
Am J Manag Care 2007 Jul; 13:(7):401-7
http://www.ajmc.com/Article.cfm?ID=3338&CFID=10776678&CFTOKEN=50788056

Abstract:

OBJECTIVE: To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions.

STUDY DESIGN: We reviewed the quality of economic analyses in dossiers submitted to Premera Blue Cross Health Plan (Mountlake Terrace, Washington; enrollment 1.6 million) between January 2002 and September 2005. For dossiers submitted in 2003, we examined the clinical studies included.

METHODS: Dossiers were audited with a data collection form to judge the types of clinical studies used to support labeled and off-label indications, and the quality and transparency of economic analyses. We compared economic analyses for high-cost (30-day treatment cost > $1000) versus low-cost products, and for “innovative” versus “me-too” drugs.

RESULTS: Evidence to support off-label indications often was included in 2003 dossiers, but the information was less extensive and of poorer quality than data for labeled indications. Of 115 dossiers submitted between 2002 and 2005, 53 (46%) included economic analyses. The economic analyses had low levels of compliance with standards: only 43% performed sensitivity analysis; 38% stated the study perspective; 37% discussed relevant treatment alternatives; 20% stated assumptions clearly; and 18% mentioned caveats to conclusions. Economic analyses of high-cost products and innovative products had higher compliance with recommended practices.

CONCLUSIONS: Drug companies are submitting dossiers of evidence to formulary committees. Dossiers often included clinical data to support off-label indications, but concerns persist about their quality. About half of dossiers included economic analyses, but these analyses had relatively low levels of compliance with recommended practices.

Keywords:
Publication Types: Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. MeSH Terms: Cost-Benefit Analysis Drug Evaluation* Drug Industry* Economics, Pharmaceutical* Evidence-Based Medicine Formularies/standards* Guideline Adherence* Humans Managed Care Programs United States

Notes:

Free full text